The financial terms of the transaction were not disclosed.
Dave Hickey, president of life sciences for BD, commented, “This acquisition will enable us to expand and scale our digital capabilities in-house to speed time to market for transformative at-home solutions now and in the future.”
BD collaborated with Scanwell to develop the app used with the recently launched BD Veritor At-Home COVID-19 Test, the first at-home COVID-19 test that uses a smartphone camera and app to capture and interpret results, eliminating the human subjectivity in other visually read at-home antigen tests.
Read more from ROI-NJ:
Scanwell will become the foundational digital platform upon which BD plans to develop at-home diagnostic tests for a range of infectious diseases, including COVID-19/influenza A+B, group A strep and additional menus for detecting infections and managing chronic disease.
The Scanwell app is a key differentiator in the market for at-home COVID-19 testing. To date, no other company uses the phone’s camera to capture the image of the test that is then analyzed and interpreted by the app. Other COVID-19 home tests use smartphones as part of their process, but BD Veritor At-Home COVID-19 Test is the first and only test to use the smartphone as the analyzer to digitally interpret the test results and provide a definitive positive or negative digital display of testing results. The app also has the capabilities to securely store and report test results to organizations, including businesses, public health authorities and schools. The results of tests are stored in the app and can be referenced and displayed at any time by simply logging into the app.